Sufrin J R, Rattendi D, Spiess A J, Lane S, Marasco C J, Bacchi C J
Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Antimicrob Agents Chemother. 1996 Nov;40(11):2567-72. doi: 10.1128/AAC.40.11.2567.
Fifteen purine nucleosides and their O-acetylated ester derivatives were examined for in vitro antitrypanosomal activity against the LAB 110 EATRO isolate of Trypanosoma brucei brucei and two clinical isolates of Trypanosoma brucei rhodesiense. Initial comparisons of activity were made for the LAB 110 EATRO isolate. Three nucleoside analogs exhibited no significant activity (50% inhibitory concentrations [IC50s] of > 100 microM), whether they were O acetylated or unacetylated; three nucleosides showed almost equal activity (IC50s of < 5 microM) for the parent compound and the O-acetylated derivative; nine nucleosides showed significantly improved activity (> or = 3-fold) upon O acetylation; of these nine analogs, six displayed activity at least 10-fold greater than that of their parent nucleosides. The most significant results were those for four apparently inactive compounds which, upon O acetylation, displayed IC50s of < or = 25 microM. When the series of compounds was tested against T. brucei rhodesiense isolates (KETRI 243 and KETRI 269), their antitrypanosomal effects were comparable to those observed for the EATRO 110 strain. Thus, our studies of purine nucleosides have determined that O acetylation consistently improved their in vitro antitrypanosomal activity. This observed phenomenon was independent of their cellular enzyme targets (i.e., S-adenosylmethionine, polyamine, or purine salvage pathways). On the basis of our results, the routine preparation of O-acetylated purine nucleosides for in vitro screening of antitrypanosomal activity is recommended, since O acetylation transformed several inactive nucleosides into compounds with significant activity, presumably by improving uptake characteristics. O-acetylated purine nucleosides may offer in vivo therapeutic advantages compared with their parent nucleosides, and this possibility should be considered in future evaluations of this structural class of trypanocides.
对15种嘌呤核苷及其O - 乙酰化酯衍生物进行了体外抗锥虫活性检测,检测对象为布氏布氏锥虫的LAB 110 EATRO分离株以及两种罗德西亚布氏锥虫临床分离株。首先对LAB 110 EATRO分离株进行了活性比较。三种核苷类似物无论是否经过O - 乙酰化,均未表现出显著活性(50%抑制浓度[IC50] > 100 microM);三种核苷的母体化合物和O - 乙酰化衍生物表现出几乎相同的活性(IC50 < 5 microM);九种核苷经O - 乙酰化后活性显著提高(≥ 3倍);在这九种类似物中,六种的活性比其母体核苷至少高10倍。最显著的结果是四种看似无活性的化合物,经O - 乙酰化后,IC50 ≤ 25 microM。当该系列化合物针对罗德西亚布氏锥虫分离株(KETRI 243和KETRI 269)进行测试时,其抗锥虫效果与EATRO 110菌株相当。因此,我们对嘌呤核苷的研究确定,O - 乙酰化可持续提高其体外抗锥虫活性。这一观察到的现象与其细胞酶靶点(即S - 腺苷甲硫氨酸、多胺或嘌呤补救途径)无关。基于我们的结果,建议常规制备O - 乙酰化嘌呤核苷用于体外抗锥虫活性筛选,因为O - 乙酰化大概通过改善摄取特性将几种无活性的核苷转化为具有显著活性的化合物。与母体核苷相比,O - 乙酰化嘌呤核苷可能具有体内治疗优势,在未来对这类结构的锥虫杀灭剂进行评估时应考虑这种可能性。